Effects of MTHFR and ABCC2 gene polymorphisms on antiepileptic drug responsiveness in Jordanian epileptic patients

Laith N AL-Eitan¹,²
Islam M Al-Dalalah¹
Mohamed M Mustafa³
Mansour A Alghamdi⁴
Afrah K Elshammari⁵
Wael H Khreisat⁵
Hanan A Aljamal¹

¹Department of Applied Biological Sciences, Jordan University of Science and Technology, Irbid, Jordan; ²Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid, Jordan; ³Department of Neuroscience, Jordan University of Science and Technology, Irbid, Jordan; ⁴College of Medicine, King Khalid University, Abha, Saudi Arabia; ⁵Queen Rania Hospital for Children, King Hussein Medical Center, Royal Medical Services, Amman, Jordan

Background: Epilepsy is one of the most common neurological diseases with unclear etiology where its genetic background and treatment regime still need further exploration.

Objectives: This study designed to evaluate the pharmacogenomics of MTHFR and ABCC2 genes, and their association with epilepsy susceptibility among Jordanian population.

Methods: A case-control study was conducted on Jordanian cohort of 296 epileptic patients and 299 healthy individuals. Custom platform array was used to genotype the genetic polymorphisms within MTHFR (rs1801133) and ABCC2 (rs717620, rs3740066, rs2273697) genes.

Results: This study revealed a significant genetic association of MTHFR rs1801133 polymorphism with susceptibility to generalized in general and generalized tonic-clonic epilepsy (GTCE) (p=0.018 and 0.01, respectively). Regarding ABCC2 gene, rs717620 was of linkage with generalized and GTCE subtypes (p=0.045 and 0.048, respectively), while rs717620 was associated with poor responder patients (p=0.036) with no linkage of the ABCC2 haplotypes.

Conclusions: MTHFR and ABCC2 polymorphisms showed an association with either epilepsy types in general or subtypes and treatment response among Jordanian population. This study also suggested that these gene polymorphisms have an important role in epilepsy development and drug effectiveness and could be of a great impact in the era of epilepsy diagnosis and treatment.

Keywords: methylenetetrahydrofolate reductase deficiency, epilepsy, pharmacogenetics, tonic-clonic epilepsy, psychotic disorders

Introduction

Epilepsy is one of the most common neurological diseases with a higher prevalence in developing countries.¹–⁴ It is defined as an unprovoked recurrent seizure due to abnormal recurrent firing from the brain.⁵,⁶ The exact etiology of seizure is still having uncertainty despite the great effort of investigation and analysis. The genetic basis of epilepsy is one of the most ingoing fields in the medical research. Genetic profile studies play a major role in identifying the gene involved in epilepsy development and progression and classifying the disease into different subtypes.⁶ Several genetic studies were also conducted on families and twins with epilepsy, suggested that genetic background has an essential role in disease development and progression.⁷–¹⁰

Pharmacogenomic studies play a major role in exploring the genetic factors that may influence the responsiveness status of patients to their prescribed medications.¹¹ Based on previous studies, genetic polymorphisms were found to be implicated in
pharmacokinetic and pharmacodynamic of antiepileptic drugs (AEDs).\textsuperscript{12,13} ATP-binding cassette subfamily C member 2 (\textit{ABCC2}) gene encodes multidrug resistance protein (MRP) which is gaining more attention recently since it has been suggested in different studies and plays a significant role in epilepsy development and its treatment.\textsuperscript{-14-18} One possible theory is about its effect on AEDs efflux in the blood-brain barrier, which may decrease the concentration of AEDs at the site of action.\textsuperscript{19} MRP protein is found to be associated with multidrug resistance especially in tumor cells, but recently, it found to be associated with resistance to AED treatment.\textsuperscript{20-22} The gene encoding 5, 10-methylenetetrahydrofolate reductase (MTHFR) enzyme is known to reduce methylene tetrahydrofolate to methyl tetrahydrofolate.\textsuperscript{23} Any defect in this enzyme may increase the level of homocysteine and decrease the level of methionine. Elevated homocysteine level is frequently found in patients with epilepsy (PWE), and it is associated with increased risk of cardiovascular disease in epileptic patients.\textsuperscript{24,25} Patients with MTHFR deficiency rapidly develop neurological symptoms such as seizure, stroke, and incoordination.\textsuperscript{26} However, early and aggressive treatment can improve the clinical outcome.\textsuperscript{27,28}

In this study, the genetic association of \textit{MTHFR} and \textit{ABCC2} gene polymorphisms in PWE was evaluated as a continuation of an extended study to assess the genetic variety of epilepsy and responsiveness to treatment in the Jordanian Arab population.

**Materials and methods**

**Study population and treatment protocol**

A pharmacogenetics and case-control study was conducted on Jordanian cohort (595 participants) of 296 PWE and 299 healthy controls. PWE were recruited in the period between 2017 and 2018 from the Neuro-Pediatric Clinic at Queen Rania Al Abdullah Hospital (QRAH). The healthy individuals were recruited from the Blood Bank at the Jordanian Royal Medical Services. All subjects gave their informed consent for inclusion before they participated. The study was conducted in accordance with the Declaration of Helsinki 1975, as revised in 2013, and the protocol was approved by the Ethics Committee at Jordan University of Science and Technology (16/111/2017). According to the last classification by international league against epilepsy, epilepsy has been classified to focal onset and generalized onset. Generalized onset is containing motor, which further classified to tonic-clonic, myoclonic and others.\textsuperscript{29,30} PWE were children under 15 years of age, having at least two attacks of seizures within more than 24 hrs apart in the last six months, and receiving antiepileptic treatment for at least three months. Patients were excluded if there was no sufficient medical record, not complaint to the AED, there was non-reliable seizure frequency, had liver disease, was not visiting the clinics regularly, or refused to sign the written consent. Participants should also have normal psychometric development, normal activity in addition to normal neurological examination.

A total of 450 patients were screened with only 350 patients fulfilled the inclusion criteria, but 50 of them were excluded as they were not able to complete the treatment program for clinical reasons or refused to continue the treatment. This cohort was conducted on 300 patients, where four of them were excluded due to a genotyping failure resulted in a final population of 296 PWE. Patients’ demographic data were published previously as this study is a continuation of extended study by AL-Eitan et al, that assessed the pharmacogenetics and epilepsy association with different genetic polymorphisms.\textsuperscript{31}

Participated patients received antiepileptics for at least two years regarding the standard Practice of the Pediatric Neurology Clinic at the QRAH. Antiepileptic treatment protocol began with 10 mg/kg of valproic acid (VPA) (G.L. Pharma GmbH, Lannach, Austria) for patients diagnosed with generalized seizure or 5 mg/kg daily of carbamazepine (CBZ) (Novartis Pharmaceuticals UK Ltd., Surrey, England) for patients diagnosed with partial seizure. To ensure the dose effectiveness, Seizure was frequency monitored for the first three to four weeks after initiation of the therapy. Patients were given the therapeutic dose by increasing the initial VPA and CBZ doses to 20 and 10 mg/kg, respectively, during follow-up visits in order to minimize seizure frequency.

**Outcome measure**

Patients were classified according to their AEDs responsiveness to good and poor responders. Patients were considered as a good responder when

Epilepsy in which the patient receiving the current AED regimen has been seizure-free for a minimum of three times the longest preintervention interseizure interval or 12 months, whichever is longer.\textsuperscript{32}

On the other hand, poor responders (ie, resistant) were classified based on the “failure of adequate trials of two tolerated and appropriately chosen and used AED
schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom.32

SNP selection and genotyping
Four SNPs were selected from databases such as SNP database of the National Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/SNP/), Applied Biosystems SNP database (http://www.appliedbiosystems.com), and Ensembl database (http://www.ensembl.org/index.html). For the ABCC2 gene, rs717620, rs3740066, and rs2273697 were selected and only rs1801133 for the MTHFR gene. DNA was extracted from EDTA blood samples by Wizard Genomic DNA Puriﬁcation Kit (Promega Corporation, Madison, WI, USA) and genotyped by the Australian Genome Research Facility (AGRF) following the manufacturer’s recommendation using the MassARRAY (iPLEX GOLD) system (Sequenom, San Diego, CA, USA).

Statistical analysis
Genetic and haplotype association analysis were conducted for the selected SNPs to find out any association if present. Analysis was performed using SNPStats Web Tool (https://www.snpstats.net/start.htm) in addition to Hardy–Weinberg equilibrium values for the genotype distribution and the minor allelic frequency. The Statistical Package for Social Sciences (SPSS) software (v. 22) was also used to conduct all statistical analyses for phenotype–genotype study. p-value less than 0.05 was considered to be statistically significant.

Table 1 The distributions of ABCC2 and MTHFR SNPs in 296 patients with epilepsy and 299 healthy controls

| Gene  | SNP ID     | Model             | Epileptic patients % | Controls % | p-value* |
|-------|------------|-------------------|----------------------|------------|----------|
| **MTHFR** | rs1801133 | GG/AG/AA          | 51.7/38.9/9.5        | 46.8/42.5/10.7 | 0.49     |
|       |           | GG/(AG+AA)        | 51.7/48.3            | 46.8/53.2 | 0.24     |
|       |           | (GG+AG)/AA        | 90.5/9.5             | 89.3/10.7 | 0.61     |
| **ABCC2** | rs717620 | CC/CT/TT          | 79.3/19.3/1.4        | 79.9/19.7/0.3 | 0.37     |
|       |           | CC/(CT+TT)        | 79.3/20.7            | 79.9/20.1 | 0.85     |
|       |           | (CC+TC)/TT        | 98.6/1.4             | 99.7/0.3 | 0.16     |
|       | rs3740066 | CC/CT/TT          | 49.1/41.4/9.5        | 46/44.3/9.7 | 0.73     |
|       |           | CC/(CT+TT)        | 49.1/50.9            | 46/54     | 0.44     |
|       |           | (CC+CT)/TT        | 90.5/9.5             | 90.3/9.7 | 0.92     |
|       | rs2273697 | GG/AG/AA          | 58.1/36.8/5.1        | 54/40.2/5.7 | 0.61     |
|       |           | GG/(AG+AA)        | 58.1/41.9            | 54/46     | 0.32     |
|       |           | (GG+AG)/AA        | 94.9/5.1             | 94.3/5.7 | 0.72     |

Note: *Chi-Square Test with p<0.05 is considered significant.

Results
Genotypic and allelic distribution
In comparison between healthy controls and epileptic patients, no genetic association exhibited in the studied SNPs of MTHFR (rs1801133), and ABCC2 (rs717620, rs3740066, rs2273697) (Table 1).

Association of MTHFR and ABCC2 SNPs with epilepsy classes and AED responsiveness
Patients were classified into patients with generalized onset epilepsy (GE) and patients with focal onset epilepsy (FE). GE patients showed a statistically significant linkage with MTHFR rs1801133 (p=0.018). ABCC2 rs717620 was also associated with GE as TT was revealed in 2.3% of GE in compare to 0.3% in healthy controls (p=0.045) (Table 2). GE patients were further classified into patients with generalized myoclonic epilepsy (GME), and generalized tonic-clonic epilepsy (GTCE). All the investigated SNPs within both genes were lacked any association in GME patients (Table 3). In GTCE, MTHFR rs1801133 was of a significant relation, as GG was presented in 60.9% of GTCE patients in compare to 46.8% in healthy individuals (p=0.01). In addition, ABCC2 rs717620 was also associated with GTCE patients (p=0.048) (Table 4). On the other hand, scanned polymorphisms were failed to be associated with FE type (Table 5).

Regarding their response to an AED, patients were classified into good responders and poor responders. Studied genes exhibited no relationship with either poor...
or good responders (Table 6) except for the ABCC2 rs717620 that found to be associated with the poor responders’ group (p=0.036).

**Association of the ABCC2 haplotypes with epilepsy susceptibility and treatment responsiveness**

Five haplotypes were found for ABCC2 gene where CCA and CTG blocks showed significant association with GME susceptibility as their frequency was higher in controls (0.23% vs 0.12%, p=0.0069 and 0.2 vs 0.13, p=0.034, respectively) (Table 7). Regarding patients’ response to AED, none of the ABCC2 haplotypes were found to be associated with either poor or good responders (data not shown).

**Association between MTHFR and ABCC2 SNPs and the patients’ phenotype**

Seven clinical characteristics were investigated in relation to the MTHFR and ABCC2 genes including the history of febrile seizure, family history of epilepsy, psychosis, suicidal thoughts or actions, epilepsy syndromes, classification of epilepsy and response to the first drug. None of the aforementioned phenotypes were associated with MTHFR (Table 8). ABCC2 rs3740066 was predominant in individuals with suicidal thoughts or actions (p=0.007) where

---

**Table 2** The distributions of ABCC2 and MTHFR SNPs in 172 patients with generalized epilepsy (GE) and 299 healthy controls

| Gene  | SNP ID    | Model                       | GE patients %              | Controls %                | p-value*   |
|-------|-----------|-----------------------------|----------------------------|---------------------------|------------|
| MTHFR | rs1801133 | GG/GA/AA                    | 58.1/33.7/8.1              | 46.8/42.5/10.7            | 0.06       |
|       |           | GG/(GA+AA)                  | 58.1/41.9                  | 46.8/53.2                 | 0.018      |
|       |           | (GA+AG)/AA                  | 91.9/8.1                   | 89.3/10.7                 | 0.36       |
|       | rs717620  | CC/CT/TT                    | 80.1/17.5/2.3              | 79.9/19.7/0.3             | 0.12       |
|       |           | CC/(CT+TT)                  | 80.1/19.9                  | 79.9/20.1                 | 0.96       |
|       |           | (CC+TC)/TT                  | 97.7/2.3                   | 99.7/0.3                  | 0.045      |
|       | rs3740066 | CC/CT/TT                    | 48.8/40.7/10.5             | 46.4/43.9/9.7             | 0.75       |
|       |           | CC/(CT+TT)                  | 48.8/51.2                  | 46/54                     | 0.55       |
|       |           | (CC+TC)/TT                  | 89.5/10.5                  | 90.3/9.7                  | 0.8        |
|       | rs2273697 | GG/GA/AA                    | 57/38/4.7                  | 54/40.2/5.7               | 0.78       |
|       |           | GG/(GA+AA)                  | 57/43                      | 54/46                     | 0.54       |
|       |           | (GA+AG)/AA                  | 95.3/4.7                   | 94.3/5.7                  | 0.61       |

**Note:** *Chi-Square Test with P<0.05 is considered significant.

---

**Table 3** The distributions of ABCC2 and MTHFR SNPs in 57 generalized myoclonic epileptic (GME) patients and 299 healthy controls

| Genes  | SNP ID    | Model                       | GME patients %              | Controls %                | p-value*   |
|--------|-----------|-----------------------------|----------------------------|---------------------------|------------|
| MTHFR  | rs1801133 | GG/GA/AA                    | 52.6/40.4/7                | 46.8/42.5/10.7            | 0.58       |
|        |           | GG/(GA+AA)                  | 52.6/47.4                  | 46.8/53.2                 | 0.42       |
|        |           | (GG+AG)/AA                  | 93/7                       | 89.3/10.7                 | 0.38       |
|        | rs717620  | CC/CT/TT                    | 80.7/17.5/1.8              | 79.9/19.7/0.3             | 0.51       |
|        |           | CC/(CT+TT)                  | 80.7/19.3                  | 79.9/20.1                 | 0.89       |
|        |           | (CC+TC)/TT                  | 98.2/1.8                   | 99.7/0.3                  | 0.26       |
|        | rs3740066 | CC/CT/TT                    | 49.1/42.1/8.8              | 46/44.3/9.7               | 0.9        |
|        |           | CC/(CT+TT)                  | 49.1/50.9                  | 46/54                     | 0.66       |
|        |           | (CC+TC)/TT                  | 91.2/8.8                   | 90.3/9.7                  | 0.82       |
|        | rs2273697 | GG/GA/AA                    | 66.7/29.8/3.5              | 54/40.2/5.7               | 0.2        |
|        |           | GG/(GA+AA)                  | 66.7/33.3                  | 54/46                     | 0.076      |
|        |           | (GA+AG)/AA                  | 96.5/3.5                   | 94.3/5.7                  | 0.47       |

**Note:** *Chi-Square Test with P<0.05 is considered significant.
rs2273697 showed an association with the classification of epilepsy ($p=0.002$) (Table 8).

**Discussion**

In this study, our Jordanian cohort was used to investigate the genetic association of MTHFR and ABCC2 gene polymorphisms with the susceptibility to develop epilepsy and responsiveness to treatment. rs1801133 SNP within the MTHFR gene was found to be associated with epilepsy. The frequency of the rare homogenous genotype of this SNP in healthy controls was 10.7%, which is the highest in the Middle East, as it was reported to be less than 3% in Yemeni people, 7.5% in Turkey, and less than 1% in sub-Saharan Africa, but it is almost consistent with what was reported in Japan (10.2%). The highest percentage was reported in Italian and Hispanics people, which is around 20–25%. Up to date, no data have been published regarding its frequency in Jordanian Arab population.

### Table 4 The distributions of ABCC2 and MTHFR SNPs in 115 generalized tonic-clonic epileptic (GTCE) patients and 299 healthy controls

| Genes | SNP ID    | Models                     | GTCE patients % | Control % | $p$-value* |
|-------|-----------|----------------------------|-----------------|-----------|------------|
| MTHFR | rs1801133 | GG/AG/AA                   | 60.9/30.4/8.7   | 46.8/42.5/10.7 | 0.035      |
|       |           | GG/(AG+AA)                 | 60.9/39.1       | 46.8/53.2  | 0.01       |
|       |           | (GG+AG)/AA                 | 91.3/8.7        | 89.3/10.7  | 0.54       |
|       | rs717620  | CC/CT/TT                   | 79.8/17.5/2.6   | 79.9/19.7/0.3 | 0.13       |
|       |           | CC/(CT+TT)                 | 79.8/20.2       | 79.9/20.1  | 0.98       |
|       |           | (CC+TC)/TT                 | 97.4/2.6        | 99.7/0.3   | 0.048      |
|       | rs3740066 | CC/CT/TT                   | 48.7/40/11.3    | 46/44.3/9.7 | 0.71       |
|       |           | CC/(CT+TT)                 | 48.7/51.3       | 46/54      | 0.62       |
|       |           | (CC+CT)/TT                 | 88.7/11.3       | 90.3/9.7   | 0.64       |
|       | rs2273697 | GG/AG/AA                   | 52.2/42.6/5.2   | 54/40.2/5.7 | 0.9        |
|       |           | GG/(AG+AA)                 | 52.2/47.8       | 54/46      | 0.73       |
|       |           | (GG+AG)/AA                 | 94.8/5.2        | 94.3/5.7   | 0.83       |

*Note: *Chi-Square Test with $p<0.05$ is considered significant.

### Table 5 The distributions of ABCC2 and MTHFR SNPs in 124 focal onset epileptic patients and 299 healthy controls

| Genes | SNP ID    | Model                     | PE patients % | Control % | $p$-value* |
|-------|-----------|----------------------------|---------------|-----------|------------|
| MTHFR | rs1801133 | GG/AG/AA                  | 42.7/46/11.3  | 46.8/42.5/10.7 | 0.74       |
|       |           | GG/(AG+AA)                | 42.7/57.3     | 46.8/53.2  | 0.44       |
|       |           | (GG+AG)/AA                | 88.7/11.3     | 89.3/10.7  | 0.86       |
|       | rs717620  | CC/CT/TT                  | 78.2/21.8/0.0 | 79.9/3/9.9  | 0.64       |
|       |           | CC/(CT+TT)                | 78.2/21.8     | 79.9/20.1  | 0.69       |
|       |           | (CC+TC)/TT                | 100/0.0       | 99.7/0.3   | 0.4        |
|       | rs3740066 | CC/CT/TT                  | 49.6/42.3/8.1 | 46/44.3/9.7 | 0.75       |
|       |           | CC/(CT+TT)                | 49.6/50.4     | 46/54      | 0.5        |
|       |           | (CC+CT)/TT                | 91.9/8.1      | 90.3/9.7   | 0.6        |
|       | rs2273697 | GG/AG/AA                  | 59.7/34.7/5.7 | 54/40.2/5.7 | 0.55       |
|       |           | GG/(AG+AA)                | 59.7/40.3     | 54/46      | 0.29       |
|       |           | (GG+AG)/AA                | 94.3/5.7      | 94.3/5.7   | 0.97       |

*Note: *Chi-Square Test with $p<0.05$ is considered significant.
the strong relation between MTHFR rs1801133 and epilepsy subclasses and highlight the importance of subdividing patients according to the disease subtypes.

None of the studied SNPs within the ABCC2 gene were associated with epilepsy in general. Nevertheless, the association of ABCC2 rs717620 with GE and GTCE was reported in this work for the first time. However, previous studies were focused on the genetic association with patients’ responsiveness to AED treatment, there is no adequate data that are available regarding the susceptibility to epilepsy in general or epilepsy subclasses.44–47 One of the largest meta-analysis studies performed by Grover and Kukreti explored

| Genes | SNP ID | Model | Poor responder patients % | Good responder controls % | p-valuea |
|-------|--------|-------|---------------------------|---------------------------|---------|
| MTHFR | rs1801133 | GG/AG/AA | 53.2/36.8/9.9 | 50/41.1/8.9 | 0.75 |
| | | GG/(AG+AA) | 53.2/46.8 | 50/50 | 0.59 |
| | | (GG+AG)/AA | 90.1/9.9 | 91.1/8.9 | 0.76 |
| ABCC2 | rs717620 | CC/TC/TT | 80.1/17.5/2.3 | 78.9/21.1/0 | 0.089 |
| | | CC/(TC+TT) | 80.1/19.9 | 78.9/21.1 | 0.79 |
| | | (CC+TC)/TT | 97.7/2.3 | 100/0 | 0.036 |
| | rs3740066 | CC/CT/TT | 50/40.6/9.4 | 48.4/42.7/8.9 | 0.93 |
| | | CC/(CT+TT) | 50/50 | 48.4/51.6 | 0.78 |
| | | (CC+CT)/TT | 90.6/9.4 | 91.1/8.9 | 0.87 |
| | rs2273697 | GG/AG/AA | 57.3/47.4/5.3 | 58.9/36.3/4.8 | 0.96 |
| | | GG/(AG+AA) | 94.7/5.3 | 95.2/4.8 | 0.79 |
| | | (GG+AG)/AA | 94.6 | 95.7/4.3 | 0.87 |

Note: aChi-Square Test with P<0.05 is considered significant.

| Gene | Haplotypes | GMEP (%) | Controls (%) | Odds ratio (95% CI) | p-valuea |
|------|------------|----------|--------------|---------------------|---------|
| ABCC2 | CCG | 0.576 | 0.4411 | 1.00 | – |
| | CCA | 0.1257 | 0.2313 | 0.40 (0.20–0.77) | 0.0069 |
| | CTG | 0.1346 | 0.2001 | 0.49 (0.26–0.95) | 0.034 |
| | TTG | 0.1052 | 0.0932 | 0.83 (0.41–1.70) | 0.61 |
| | CTA | 0.0584 | 0.0255 | 1.63 (0.55–4.80) | 0.38 |

Notes: aChi-Square Test with P<0.05 is considered significant. Global haplotype association p-value: 0.029.

| Clinical characteristic | MTHFR rs2273697 | ABCC2 rs3740066 | ABCC2 rs717620 | ABCC2 rs1801133 |
|-------------------------|-----------------|-----------------|-----------------|-----------------|
| History of febrile seizure | 0.606 | 0.983 | 0.818 | 0.128 |
| Family history of epilepsy | 0.102 | 0.069 | 0.447 | 0.385 |
| Psychosis | 0.102 | 0.955 | 0.448 | 0.743 |
| Suicidal thoughts or actions | 0.921 | 0.926 | 0.007 | 0.970 |
| Epilepsy syndromes | 0.844 | 0.865 | 0.533 | 0.363 |
| Classification of epilepsy | 0.087 | 0.845 | 0.056 | 0.002 |
| Response to first drugb | 0.151 | 0.476 | 0.125 | 0.078 |

Notes: aAntiepileptic treatment protocol began with 10 mg/kg of valproic acid (VPA) for patients diagnosed with generalized seizure or 5 mg/kg daily of carbamazepine (CBZ) for patients diagnosed with partial seizure. Chi-Square Test with P<0.05 is considered significant.
eight reports with more than 2,500 patients, rs717620 was found to be a predictor for the poor response with no association observed in the other SNPs. This is consistent with our finding where rs717620 was the only associated SNP with the poor response status. This finding may have more application in the future, and this gene polymorphism may become a marker for poor responders, since the personalization of treatment is gaining more global attention.

Regarding ABCC2 haplotypes, very limited studies have been done to assess its association with epilepsy susceptibility. This study is one of few studies that found five haplotypes for ABCC2 gene with GME in a linkage to CCA and CTG, which is to the best of our knowledge was not reported in the literatures before. Qu et al, are one of the first people who find five haplotypes for ABCC2 gene, and their study showed a significant association between TGT and drug resistance. Moreover, Ufer et al, found four haplotypes for ABCC2 gene with multiple associations to drugs response in the Caucasian population. In concordance with our study, several studies did not find any association for the ABCC2 haplotypes with drug response, despite the difference in the ethnic background.

Finally, MTHFR rs180113 and ABCC2 rs717620 were found to be associated with GE and GTCE in Jordanian population. Moreover, five haplotypes for ABCC2 gene were found in this study with only CCA and CTG haplotypes were associated with GME subtype. Future studies should be directed to find the relation between genetic variations and epilepsy susceptibility and treatment response. This will lead to a promising result that expected to have a great implication in disease diagnosis and treatment in the near future.

**Abbreviation list**
AED, Antiepileptic drug; MTHFR, methenyltetrahydrofolate reductase; ABCC2, ATP-binding cassette subfamily C member 2; MRP, Multidrug resistance protein; BBB, Blood-brain barrier; GE, Generalized onset epilepsy; FE, Focal onset epilepsy; GME, Generalized myoclonic epilepsy; GTCE, Generalized tonic-clonic epilepsy; PWE, Patients with epilepsy.

**Ethics approval and informed consent**
All procedures contributing to this work complied with the ethical standards of the relevant national and institutional committees on human experimentation and the Declaration of Helsinki with an IRB no. (16/111/2017)

**Data availability**
The datasets generated and analyzed during the current study are not publicly available. The consent from participants did not cover data sharing but are available from the corresponding author on reasonable request.

**Acknowledgments**
This work was supported by the Deanship of Research at Jordan University of Science and Technology under grant number (RN: 104/2017).

**Disclosure**
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**References**

1. Sadr SS, Javanbakht J, Javidan A, Ghaffarpour M, Khamse S, Naghsband Z. Descriptive epidemiology: prevalence, incidence, sociodemographic factors, socioeconomic domains, and quality of life of epilepsy: an update and systematic review. *Arch Med Sci.* 2018;14(4):717–724.

doi:10.5114/ams.2016.60377

2. Birbeck GL. Epilepsy care in developing countries: part I of II. *Epilepsy Curr.* 2010;10(4):75–79.

doi:10.1111/j.1528-1167.2010.01362.x

3. Cowan LD. The epidemiology of the epilepsies in children. *Mont Retard Dev Disabil Res Rev.* 2002;8(3):171–181.

doi:10.1002/mrdd.10035

4. Banerjee PN, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsy – a review. *Epilepsy Res.* 2009;85(1):31–45.

5. Myers CT, Mefford HC. Advancing epilepsy genetics in the genomic era. *Genome Med.* 2015;7:91.

6. Poduri A, Lowenstein D. Epilepsy genetics–past, present, and future. *Curr Opin Genet Dev.* 2011;21(3):325–332.

7. Steinlein OK. Genes and mutations in human idiopathic epilepsy. *Brain Dev.* 2004;26(4):213–218.

8. Berkovic SF, Howell RA, Hay DA, Hopper JL. Epilepsies in twins: genetics of the major epilepsy syndromes. *Ann Neurol.* 1998;43(4):435–445.

9. Kjeldsen MJ, Kyvik KO, Friis ML, Christensen K. Genetic and environmental factors in febrile seizures: a Danish population-based twin study. *Epilepsy Res.* 2002;51(1–2):167–177.

10. Kjeldsen MJ, Corey LA, Christensen K, Friis ML. Epileptic seizures and syndromes in twins: the importance of genetic factors. *Epilepsy Res.* 2003;55(1–2):137–146.

11. Orlandi A, Paolino MC, Striano P, Parisi P. Clinical reappraisal of the influence of drug-transporter polymorphisms in epilepsy. *Expert Opin Drug Metab Toxicol.* 2018;14(5):505–512.

doi:10.1080/17425255.2018.1473377

12. Loscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. *Epilepsia.* 2009;50(1):1–23.

doI:10.1111/j.1528-1167.2008.01716.x

13. Loscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. *J Pharmacol Exp Ther.* 2002;301(1):7–14.

14. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. *Genome Res.* 2001;11(7):1156–1166.

doI:10.1101/gr.184901

15. Myers CT, Mefford HC. Advancing epilepsy genetics in the genomic era. *Genome Med.* 2015;7:91.

16. Poduri A, Lowenstein D. Epilepsy genetics–past, present, and future. *Curr Opin Genet Dev.* 2011;21(3):325–332.

17. Steinlein OK. Genes and mutations in human idiopathic epilepsy. *Brain Dev.* 2004;26(4):213–218.

18. Berkovic SF, Howell RA, Hay DA, Hopper JL. Epilepsies in twins: genetics of the major epilepsy syndromes. *Ann Neurol.* 1998;43(4):435–445.

19. Kjeldsen MJ, Kyvik KO, Friis ML, Christensen K. Genetic and environmental factors in febrile seizures: a Danish population-based twin study. *Epilepsy Res.* 2002;51(1–2):167–177.

20. Kjeldsen MJ, Corey LA, Christensen K, Friis ML. Epileptic seizures and syndromes in twins: the importance of genetic factors. *Epilepsy Res.* 2003;55(1–2):137–146.

21. Orlandi A, Paolino MC, Striano P, Parisi P. Clinical reappraisal of the influence of drug-transporter polymorphisms in epilepsy. *Expert Opin Drug Metab Toxicol.* 2018;14(5):505–512.

doI:10.1080/17425255.2018.1473377

22. Loscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. *Epilepsia.* 2009;50(1):1–23.

doI:10.1111/j.1528-1167.2008.01716.x

23. Loscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. *J Pharmacol Exp Ther.* 2002;301(1):7–14.

24. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. *Genome Res.* 2001;11(7):1156–1166.

doI:10.1101/gr.184901
AL-Eitan et al.

15. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92(16):1295–1302. doi:10.1093/jnci/92.16.1295

16. Zimprich F, Sunder-Plassmann R, Stogmann E, et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology. 2004;63(6):1087–1089. doi:10.1212/01.wnl.0000141021.42763.f6

17. Muhrer K, Largeau B, Emond P, et al. Single nucleotide polymorphisms of ABC22 modulate renal secretion of endogenous organic anions. Biochem Pharmacol. 2017;140:124–138. doi:10.1016/j.bcp.2017.05.012

18. Ibbotson K, Yell J, Ronaldson PT. Nr2 signaling increases expression of ATP-binding cassette subfamily C mRNA transcripts at the blood-brain barrier following hypoxia-reoxygenation stress. Fluids Barriers CNS. 2017;14(1):6. doi:10.1186/s12987-017-0054-5

19. Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005;46(2):224–235. doi:10.1111/j.0013-5855.2005.31904.x

20. Lazarowski A, Lubienniack F, Camarero S, et al. Multidrug resistance proteins in tuberous sclerosis and refractory epilepsy. Pediatr Neurol. 2012;47(2):102–106. doi:10.1016/j.pediatrneurol.2012.02.005

21. Mazerkka Z, Mroz A, Pawlowska M, Augustin E. The role of glucuronidation in drug resistance. Pharmacol Ther. 2016;159:35–55. doi:10.1016/j.pharmthera.2016.01.009

22. Li HY, Liu F, Wang HR. Correlation between Nurr1 expression and drug resistance in the brain of rats with epilepsy. Eur Rev Med Pharmacol Sci. 2018;22(5):1506–1513. doi:10.26355/eurrev_201803.14500

23. D’Aco KE, Bearden D, Watkins D, Hyland K, Rosenblatt DS, Ficicioglu C. Severe 5,10-methylenetetrahydrofolate reductase deficiency. Eur Rev Med Pharmacol Sci. 2018;22(16):530. doi:10.1111/1525-1259.ep12670

24. Parrish RR, Buckingham SC, Mascia KL, et al. Methionine increases anions. Pediatr Res. 2000;47(4):462–471. doi:10.1016/S0887-8994(03)00407-7

25. Mazarika Z, Mroz A, Pawlowska M, Augustin E. The role of glucuronidation in drug resistance. Pharmacol Ther. 2016;159:35–55. doi:10.1016/j.pharmthera.2016.01.009

26. Urreizti R, Moya-Garcia AA, Pino-Angeles A, et al. Molecular characterization of five patients with homocystinuria due to severe methylenetetrahydrofolate reductase deficiency. Clin Genet. 2010;78(5):441–448. doi:10.1111/j.1399-0004.2010.01391.x

27. Schiff M, Benoist JF, Tilea B, Rozen R, Giraudier S, Ogier de Baulny H. Isolated remethylation disorders: do our treatments benefit patients? J Inherit Metab Dis. 2011;34(1):137–145. doi:10.1007/s10545-010-9210-8

28. Ogier de Baulny H, Gerard M, Saudubray JM, Zittoun T. Remethylation defects: guidelines for clinical diagnosis and treatment. Eur J Pediatr. 1998;157(2):S77–S83.

29. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International league against epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):522–530. doi:10.1111/epi.13670

30. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):512–521. doi:10.1111/epi.13709

31. AL-Eitan LN, Al-Dalalah IM, Elshammarri AK, Khreisat WH, Almasri AY. The impact of potassium channel gene polymorphisms on antiepileptic drug responsiveness in Arab patients with epilepsy. J Pers Med. 2018;8(4):37. doi:10.3390/jpm08040037

32. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010;51(6):1069–1077. doi:10.1111/j.1528-1167.2009.02397.x

33. Schneider JA, Rees DC, Liu YT, Clegg JB. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet. 1998;62(5):1258–1260. doi:10.1086/301836

34. Boduroglu K, Alkassiosoglu M, Anar B, Tuncbilek E. 677→CT mutation on the methylenetetrahydrofolate reductase gene is not a risk factor for neural tube defects in Turkey. Arch Dis Child Fetal Neonatal Ed. 1998;78(3):F235. doi:10.1136/fn.78.3.F234c

35. Morita H, Taguchi J, Kurihara H, et al. [Gene polymorphism of 5, 10-methylenetetrahydrofolate reductase as a coronary risk factor]. J Cardioi. 1997;29(6):309–315.

36. Shaw GM, Rozen R, Finnell RH, Wasserman CR, Lammer EJ. Maternal vitamin use, genetic variation of infant methylenetetrahydrofolate reductase, and risk for spina bifida. Am J Epidemiol. 1998;148(1):30–37. doi:10.1093/oxfordjournals.aje.a009555

37. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol. 2000;151(9):862–877.

38. Hamidi AK, Yazdani S, Seyedjavadi KH, et al. MTHFR AND ApoE genotypes linked to sudden sensorineural hearing loss. Am J Otolaryngol. 2019;40(2):260–264.

39. Wu YL, Ding XX, Sun YH, Yang HY, Sun L. Methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphisms and susceptibility to Parkinson’s disease: a meta-analysis. J Neurol Sci. 2013;335(1–2):14–21.

40. Hua Y, Zhao H, Kong Y, Ye M. Association between the MTHFR gene and Alzheimer’s disease: a meta-analysis. Int J Neurosci. 2011;121(8):462–471.

41. Azimova JE, Sergeev AV, Korobeynikova LA, et al. Effects of MTHFR gene polymorphism on the clinical and electrophysiological characteristics of migraine. BMC Neurol. 2013;13:103.

42. Scher AI, Wu H, Tsao JW, et al. MTHFR C677T genotype as a risk factor for epilepsy including post-traumatic epilepsy in a representative military cohort. J Neurotrauma. 2011;28(9):1739–1745.

43. Wu YL, Yang HY, Ding XX, et al. Association between methylenetetrahydrofolate reductase C677T polymorphism and epilepsy susceptibility: a meta-analysis. Seizure. 2014;23(6):411–416.

44. Xue T, Lu ZN. Association between the polymorphisms in the ATP-binding cassette genes ABCB1 and ABCC2 and the risk of drug-resistant epilepsy in a Chinese Han population. Genet Mol Res. 2016;15(4).

45. Zhou L, Cao Y, Long H, et al. ABCC2 gene polymorphisms and drug resistant epilepsy in the Chinese Han population. Pharmazie. 2015;70(6):416–420.

46. Grover S, Kukreti R. A systematic review and meta-analysis of the role of ABCC2 variants on drug response in patients with epilepsy. Epilepsia. 2013;54(5):936–945.

47. Hilger E, Reinthaler EM, Stogmann E, et al. Lack of association between methyleneetetrahydrofolate reductase C677T polymorphism and epilepsy susceptibility: a meta-analysis. Seizure. 2014;23(6):411–416.
